Scientists led by EPFL have successfully induced breast cancer cells in mice, allowing them to study in vivo cross-sectional interactions between isrogen receptors and progesterone receptor antagonists. Their findings suggest that endocrine therapy may need to be specialized, and eliminating progesterone receptor expression may be a therapeutic option.
“Breast cancer affects 1 in 7 women,” said Professor Cathrin Brisken at the EPFL School of Life Sciences. “More than two-thirds of cases are sensitive to hormones and explain the recipient to estrogen in more than 1% of the material cancer cells. “Actually, the biological signal of the isrogen receptor is a major driver of breast cancer and with its blockade it is the pursuit of hormone replacement therapy, which improves the quality of life of patients.
The problem is that tumors that are positive for the isrogen receptor are studied because the field does not have enough animal species. “Mammary carcinomas that develop in the form of mice that do not control the hormones, and the success rate of the isrogen-positive receptor. breast cancer xenografts are very low. “
Previous studies have revealed an important “cross-talk” between an isrogen receptor and a sex hormone, progesterone. Specifically, estrogen signaling pathways as well progesterone receptors as if they were interfering with each other on the level of organic matter and protein.
However, the lack of adequate cell lines and animal species has prevented scientists from studying this cross under clinical hormone levels. Just as the progesterone receptor is affected by the isrogen receptor, the endogenous hormone therapy may block the initial expression. This complexity makes it difficult to study the role of either the receptor itself and, subsequently, improve treatment strategies.
Now, working with researchers and doctors at the University of Lausanne Hospital (CHUV), Réseau Lausannois du Sein, and the International Center for Cancer Prevention (ICPI), the Brisken laboratory has successfully grafted an isrogen-positive human receptor . Breast cancer cells to the milk supply of sick mice. The development allowed them to study the effects of estrogen and progesterone on the development of breast cancer.
Scientists have found that both hormones, estrogen and progesterone can increase the risk of cancer and the combination of treatments can increase metastasis.
But there is a way forward. “We found that tumor tumors from different patients had different responses to two hormones, suggesting that endocrine disruption could be improved by isolation,” Brisken said. “In addition, suppressing progesterone receptor expression may be a therapeutic option,” she said. “While it has been suggested that progesterone may help women with breast cancer, we have shown that the hormone has a beneficial effect on breast cancer, and it provides evidence that. progesterone receptor acting as my mediator isrogen receptor signal, making this receptor attractive as a potential therapeutic target. “
The study, published in Environmental communicationPresented by the Director of the Endocrine Society at the recent ENDO 2022 conference, which was attended by more than 7,000 doctors and scientists.
Valentina Scabia et al, Estrogen receptor positive breast cancer patients have specific hormone levels of the patient and are dependent on the progesterone receptor, Environmental communication (2022). DOI: 10.1038 / s41467-022-30898-0
Ecole Polytechnique Federale de Lausanne
hint: Cross-talk hormone development in breast cancer (2022, June 16) Retrieved 16 June 2022 from https://medicalxpress.com/news/2022-06-breakthrough-hormone-cross-talk- breast-cancer. html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
Breakthrough study of hormone ‘cross-talk’ in breast cancer Source link Breakthrough study of hormone ‘cross-talk’ in breast cancer